Cite
MLA Citation
C Campbell et al.. “P.063 SUNFISH Part 1 results and Part 2 trial design in patients with type 2/3 spinal muscular atrophy (SMA) receiving risdiplam (RG7916).” Canadian journal of neurological sciences, vol. 46, n.d., p. S31. http://access.bl.uk/ark:/81055/vdc_100084766335.0x00000e